This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

OverviewDosingTolerability ProfileSupport and ResourcesFluoropyrimidine intoleranceUse in patients with fluoropyrimidine intolerancePatient profiles
Explore more
MaterialsVideosEvents

Prescribing Information for TOMUDEX® (raltitrexed) and adverse event reporting information can be found at the bottom of the page.

TOMUDEX (raltitrexed) Dosing

​​​​Raltitrexed is a cytotoxic agent and should be handled according to normal procedures adopted for such agents1.
 

The dose of raltitrexed is calculated on the basis of the body surface area. The recommended dose is 3 mg/m2 given intravenously, as a single short, intravenous infusion in 50 to 250 ml of either 0.9% sodium chloride solution or 5% dextrose (glucose) solution. It is recommended that the infusion is given over a 15 minute period1.
 

Other drugs should not be mixed with raltitrexed in the same infusion container. In the absence of toxicity, treatment may be repeated every 3 weeks1.
 

Dose escalation above 3 mg/m2 is not recommended, since higher doses have been associated with an increased incidence of life-threatening or fatal toxicity1.

Dose adjustment for renal impairment is required1:
Tolerability Profile

Find out more about the tolerability profile of TOMUDEX

Find out moreLoading
Patient Profiles

Explore more about how TOMUDEX can support your patients 

Explore moreLoading
Fluoropyrimidine Intolerance

Learn about TOMUDEX use in patients with fluoropyrimidine intolerance
 

Learn moreLoading
Medicines

Find out more about other Pfizer products

View MedicinesLoading
Join us!

Sign up or log in now to access further materials and resource

Join NowLoading


References:

  1. TOMUDEX® Summary of Product Characteristics


 

Prescribing Information

TOMUDEX:

TOMUDEX® (raltitrexed) 2 mg powder for solution for infusion – Prescribing Information Legal Category: POM. Basic NHS Price: 1 vial £148.75
 

OXALIPLATIN:

Oxaliplatin Vial 50mg/10ml Legal Category: POM. Basic NHS Price: 1 vial £156.75
Oxaliplatin Vial 100mg/20ml Legal Category: POM. Basic NHS Price: 1 vial £313.50
Oxaliplatin Vial 200mg/40ml Legal Category: POM. Basic NHS Price: 1 vial £627.00
Oxaliplatin 5mg/ml Concentrate for Solution for Infusion - Prescribing Information 


FLUOROURACIL:

Fluorouracil Vial 500mg/20ml Legal Category: POM. Basic NHS Price: £64.00
Fluorouracil Vial 25mg/ml Legal Category: POM. Basic NHS Price: £32.00
Fluorouracil 25mg/ml Injection - Prescribing Information

Fluorouracil Vial 50mg/ml Legal Category: POM. Basic NHS Price: £64.00
Fluorouracil Vial 500mg/10ml Legal Category: POM. Basic NHS Price: £32.00
Fluorouracil Vial 2.5g/50ml Legal Category: POM. Basic NHS Price: £32.00
Fluorouracil 50mg/ml Injection - Prescribing Information



 

PP-TOM-GBR-0001. July 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 
Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro ​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​